iShares Russell 2000 ETF (IWM)

REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases.

The company tied up with Davidson Technologies and defense company Anduril Industries to develop quantum-classical hybrid applications for U.S. air and missile defense scenarios.

After years of underperformance, small caps are off to a strong start in 2026.

As of January 26, 2026, the financial landscape has undergone a seismic shift, marking the definitive end of the "Magnificent 7" era of uncontested dominance. For the first time in decades, the baton of market leadership has been passed to the small-cap arena in what analysts are calling the "Earnings

They're two of the oldest ETFs on the market, tracking two of the most well-known indexes. How does IWM match up against QQQ?

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

Small-cap stocks just beat large-cap stocks for 14 straight days.

Explore how IWM’s diversified small-cap mix and higher yield contrast with MGK’s focused tech giants and lower fees.

Explore how portfolio concentration, sector tilt, and risk profiles set these two major ETFs apart for different investor priorities.

Many of the "Magnificent Seven" stocks have been losing steam over the past year.

The company unveiled a $200 million dilution alongside a $90 million investment from healthcare technology heavyweight Medtronic.

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.